Clinical data of the CCR2high and CCR2low patients
| . | CCR2high . | CCR2low . | ||||
|---|---|---|---|---|---|---|
| . | Stage Ι . | Stage ΙΙ . | Stage ΙΙΙ . | Stage Ι . | Stage ΙΙ . | Stage ΙΙΙ . |
| Salmon and Durie | 10% | 3% | 87% | 11% | 17% | 72% |
| . | CCR2high . | CCR2low . | ||||
|---|---|---|---|---|---|---|
| . | Stage Ι . | Stage ΙΙ . | Stage ΙΙΙ . | Stage Ι . | Stage ΙΙ . | Stage ΙΙΙ . |
| Salmon and Durie | 10% | 3% | 87% | 11% | 17% | 72% |
A total of 206 newly diagnosed patients with MM were separated into 2 subgroups according to CCR2 gene expression in myeloma cells to optimize the difference in patients' proportion with major structural damage or > osteolyses using the Maxstat package. The 2 subgroups represent patients with high (ie, CCR2 signal > 3735, CCR2high) or low (ie, CCR2 signal ≤ 3735, CCR2low) CCR2 expression. Data are the percentages of patients within each subgroup with the indicated clinical or biologic parameter. CCR2high and CCR2low values were not significantly different.